At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 409 enrolled
Drug / intervention
Lamotrigine +1 moredrug
Likely dose
Lamotrigine 200mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Lamotrigine Versus Levetiracetam in the Initial Monotherapy of Epilepsy: An Open, Prospective, Multicenter, Randomized Phase III Study
In Brief
A Phase 3 clinical trial evaluating Lamotrigine and Levetiracetam for Epilepsy. Completed, enrolled 409 participants across 1 site.
Detailed Summary
The purpose of this study is to compare the efficacy, safety and tolerance of the drugs Lamotrigine and Levetiracetam in the initial monotherapy of patients with newly diagnosed epilepsy.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsEpilepsy
CountriesGermany
CollaboratorsUCB Pharma GmbH
Timeline
Phase 3CompletedFinished
20052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartMar 2005
First PostedOct 2005
Primary CompletionJun 2008
Study CompletionJan 2009
TodayJul 2026
First PostedOct 20, 2005
Enrollment StartMar 1, 2005
Primary CompletionJun 1, 2008
Study CompletionJan 1, 2009
TodayJul 2, 2026
Enrollment to primary: 3.3 yearsPosted 20.7 years ago
Interventions
Lamotriginedrug
titrate to 200mg over 10 weeks and maintained until end of week 26
Levetiracetamdrug
titrate to 2000mg/day over 22 days, maintain until the end of week 26